Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Duearity Americas Inc has signed agreements with the first clinics in the United States

Duearity

Duearity AB's subsidiary in the US, Duearity Americas Inc, has signed agreements with the first five clinics. The clinics intend to purchase Tinearity G1 for their tinnitus patients. A reasonable assessment is that approximately ten clinics in the US have entered into agreements with the company during the third quarter of 2023.

Duearity Americas Inc has signed evaluation agreements with five clinics in the United States that intend to purchase Tinearity G1 for their tinnitus patients. The agreements mean that Duearity Americas Inc can carry out the first sales during the third quarter. Duearity received market approval on June 30 this year and sales activities started immediately after that. The assessment is that Duearity Americas Inc has entered into agreements with approximately ten clinics before the end of the third quarter.

- The interest among audiology clinics in the US has so far exceeded expectations and it is clear that Tinearity G1 fills a gap in the market. We will sell the device to clinics in a few selected states and aim to enter into distribution agreements in states that we do not intend to process ourselves. Another important channel is Veteran Affairs, which could become very profitable for the company, says David Johansson, Managing Director of Duearity Americas Inc.

For more information, please contact


Fredrik Westman, CEO
+46 738 - 145 215
fredrik.westman@duearity.com 
www.duearity.com

About Duearity AB (publ)


Duearity is a medtech company that develops and produces solutions aiming to relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. The company will offer the products Tinearity and Tinearity-AI.

Tinearity G1 is CE marked, has 510(k) clearance and is sold in the EU and in the US.

Tinearity transmits white noise using Bone Conduction Technology to the inner ear in order to relieve symptoms. Tinearity AI will use artificial intelligence to help people anticipate the symptoms and relieve their discomfort.

The company is listed on Nasdaq First North. The company's headquarters are located in Malmö, Sweden.
Certified Adviser is Svensk Kapitalmarknadsgranskning AB (SKMG), www.skmg.se.
www.duearity.com.

Attachments


Duearity Americas Inc has signed agreements with the first clinics in the United States

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.